BSH 2022 | Highlights from the BSH amyloidosis session
Ashutosh Wechalekar
• 4 Apr 2022
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, gives a brief overview of a session held at BSH 2022, which focused on the diagnosis, complications, and management of amyloidosis. Dr Wechalekar also highlights the excitement surrounding the use of daratumumab with bortezomib, cyclophosphamide and dexamethasone for the future treatment of light chain (AL) amyloidosis. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honorarium/Advisory boards/Travel support: Alexion, Janssen, Attralus, GSK, Takeda
